Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-K/A
Source: 0001731122-25-000252
Chunk: 21

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-K/A
Chunk 21
---
, and other advisors to execute nondisclosure and assignment of invention agreements upon commencement of their respective
employment or engagement.

Assigned Intellectual Property

On August 16, 2022, the USPTO issued
U.S. Patent No. 11,413,338 B2, “Methods and Compositions Using Recombinant Dendritic Cells for Cancer Therapy”, pertaining
to methods and compositions for treating cancer by eliciting an immune response by administering dendritic cells expressing heterologous
proteins. This patent protects RENB-DC11:Genetically modified Allogeneic Dendritic Cells as Potential Product for Long-term Remission of Solid Tumors – Starting with Pancreatic Cancer and potential future products RENB-DC-12XX:Genetically modified Allogeneic Dendritic Cells as Potential Product for Long-term Remission of Additional Indications for twenty years. The Company
owns this patent application, through assignment as of July 15, 2019.

On June 17, 2020, a patent titled “Allogeneic
T-Cell-Based HIV Vaccine to Induce Cellular and Humoral Immunity”, US 2021/0030795 A1 for the composition and method of use concepts
for RENB-HV-12. was filed. The Company owns this patent application, through assignment as of September 28, 2021.

In-Licensed Technology

Trade Secrets and Proprietary Know-How

In addition to intellectual property
protected by patents and copyrights, we have trade secrets and proprietary know-how relating to our products, production processes, and
future strategies.

Competition

Renovaro Cube operates in a highly
competitive market with several companies developing AI-driven diagnostic platforms for early disease detection and personalized medicine.
Key competitors include Grail, Freenome, and Owkin, each utilizing advanced AI and machine learning to analyze multi-omic data for cancer
detection. While these companies focus primarily on specific diagnostic approaches, Renovaro Cube differentiates itself through its unique,
disease-agnostic AI platform that integrates various molecular data sources for differential diagnosis. Our platform’s explainable
AI system, capable of providing actionable insights and personalized treatment options, offers a distinct advantage. Despite the crowded
landscape, Renovaro Cube's scalable technology, multi-omics capabilities, and ability to process diverse biopsy sources position it as
a versatile leader in precision diagnostics, allowing us to address a broader range of clinical and research needs.